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Abstract
Background: Available iron chelation regimes in thalassaemia may achieve different changes in
cardiac and hepatic iron as assessed by MR. The aim of this study was to assess the efficacy of four
available iron chelator regimes in 232 thalassaemia major patients by assessing the rate of change
in repeated measurements of cardiac and hepatic MR.
Results:  For the heart, deferiprone and the combination of deferiprone and deferoxamine
significantly reduced cardiac iron at all levels of iron loading. As patients were on deferasirox for a
shorter time, a second analysis ("Initial interval analysis") assessing the change between the first two
recorded MR results for both cardiac and hepatic iron (minimum interval 12 months) was made.
Combination therapy achieved the most rapid fall in cardiac iron load at all levels and deferiprone
alone was significantly effective with moderate and mild iron load. In the liver, deferasirox effected
significant falls in iron load and combination therapy resulted in the most rapid decline.
Conclusion: With the knowledge of the efficacy of the different available regimes and the specific
iron load in the heart and the liver, appropriate tailoring of chelation therapy should allow clearance
of iron. Combination therapy is best in reducing both cardiac and hepatic iron, while monotherapy
with deferiprone or deferasirox are effective in the heart and liver respectively. The outcomes of
this study may be useful to physicians as to the chelation they should prescribe according to the
levels of iron load found in the heart and liver by MR.
Background
In beta thalassaemia major patients (TM) transfusions
and iron chelation therapy have significantly improved
the survival and reduced morbidity [1-4]. However, heart
complications still represent significant morbidity and
remain the leading cause of mortality [2]. In some cases
this was because of the difficulty in accepting the chela-
tion treatment with deferoxamine, which was cumber-
some [5], but problems occurred even in some patients
who accepted the chelation therapy well [6]. Surrogate
markers such as ferritin levels and liver iron concentration
(LIC), though correlated to the incidence of cardiac dis-
ease, did not have predictive value with respect to cardiac
function [7] nor to the degree of cardiac iron load [8-10].
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Liver iron reflects the total body iron load [11], and
because hepatic complications are the third most com-
mon cause of death and iron overload plays a role with
respect to the incidence of hepatic carcinoma [12], knowl-
edge of the degree of iron loading in both heart and liver
through non-invasive imaging is essential. The availability
of Magnetic Resonance Imaging (MR) [13] allows indirect
assessment of cardiac and hepatic iron. With the availabil-
ity of three iron chelators, deferoxamine (DFO),
deferiprone (DFP) and deferasirox (DFX) together with
the combination of DFO and DFP (Comb), we sought to
assess the efficacy of the available regimes on improving
cardiac and hepatic iron load as measured by T2* MR
imaging. To date there are some prospective studies that
have assessed the efficacy of the chelators, either as mon-
otherapy or in combination. In this observational study,
we analysed the efficacy of the four currently available
chelation regimes in a large clinic setting.
Methods
Patients
Patients attending our centre are usually transfused at bi-
weekly intervals maintaining a mean pre-transfusion hae-
moglobin level above 95 g/l. Chelation regimes include
DFO since the mid 1970's, DFP from 2000, combinations
of the two since 2002 [14] and after 2007 monotherapy
with DFX. All the patients on DFO were prescribed
between 30–45 mg/kg/infusion 5–7 days per week, those
on DFP between 75–100 mg/kg/day and those on DFX
between 15–40 mg/kg/day. Only two patients on DFX
were receiving 15 mg/kg/day and the mean dose for all
patients was 26.6 mg/kg/day. The doses for combination
therapy were similar to monotherapy however the days of
DFO treatment were variable with a minimum of 3 days
per week. Since MR for the assessment of cardiac and
hepatic load became available, the patients were referred
for such studies at variable intervals described in the
results. The recommended regime, doses of the individual
chelators and the frequency of DFO infusions were ini-
tially changed or adjusted according to ferritin levels and
subsequently were based on clinical features – particularly
ferritin levels and the MR findings, side effects, and
patient request. These changes were made at any time and
not necessarily related to the timing of the MR scans.
The Athens MR Imaging site (Euromedica Encephalos)
was validated by the Royal Brompton Hospital for T2*
[15]. A cardiac-dedicated General Electric 1.5 Tesla mag-
net (Signa CVI with 40 mT/m gradients and appropriate
cardiac software) was used for the MR measurements. For
cardiac T2* determination a single breath multi-echo fast
gradient-echo sequence was used with a fixed TR of 25.6
ms, 10 echoes acquired in the range of 2.2–22.6 ms and
an inter-echo spacing of about 2.2 ms). Additional imag-
ing parameters were 1 excitation, matrix of 160 × 256,
bandwidth 62.5 KHz, slice thickness of 8 mm, ECG-gating
and total acquisition time ranging from 15–20 msec. Nor-
mal values for myocardial T2* ranged between 25 to 47.6
ms (mean = 33.8 ms-1). The calculation of T2* was made
off line by an exponential least-squares fit of the multi-
echo signal intensity data (SI) versus echo time (TE), with
the use of a PC and standard fitting programs (GRAFIT or
SigmaPlot 2001).
Transfusion dependent patients with more than one MR
assessment were included in the analysis. At the time that
MR T2* for iron estimation became available, hepatic T2*
was not always performed. For this reason there are fewer
hepatic observations than cardiac.
The change in cardiac T2* was assessed according to the
chelation regime the patient was receiving during the
period spanning the MR scan. Due to the variable time
intervals between MR scans, the results are expressed as
mean annual change. Participants switched treatment
groups during the study period, therefore contributing
information to more than one regime. Only studies on
patients who were on a particular regime for more than
50% of the time interval between MR scans and the expo-
sure during that time to the particular regime was greater
than 6 months, were included in the assessment.
Equal changes in T2* correspond to disproportionate
changes in tissue iron concentration depending on the
starting T2* level [16,17]. For example an increase of 3 ms
in T2* from 5 ms to 8 ms reflects an estimated decrease in
cardiac iron of 2 mg/g. dry weight (mg/g dw) while an
equal increase in T2* from 17 ms to 20 ms corresponds to
a fall of 0.24 mg/g dw. To demonstrate changes more
quantitatively and descriptively, additional analyses were
performed according to cardiac and hepatic iron concen-
tration using an estimate of the conversion of T2* and its
changes, to mg/g dw. For the heart, we converted the T2*
to Cardiac Iron Concentration (CIC) using the formula
adapted from Wood et al [16], (1/T2*-1/T20 *)/Kdry where
T20 * is 33.8 ms (our laboratory's T20 *) and the slope,
Kdry, has been estimated at 37.4 Hz·mg-1·g dry weight-1.
For further clarification in the figures, we also show the
changes in R2* (1000/T2*) as it also has a linear relation-
ship to the cardiac iron and is more interpretable quanti-
tatively than T2*. The heavily iron loaded group included
patients with T2* < 8 ms (>2.6 mg/g dw, R2* > 125 sec-1),
moderate ³ 8 and < 14 (1.1–2.6 mg/g dw, R2* 71.4 – 125
sec-1) and mild ³ 14 and < 20 ms (0.6–1.1 mg/g dw, R2*
50–71.4 sec-1). Acceptable levels were those ³ 20 ms (<0.6
mg/g dw, R2* £  50 sec-1). Although prognostic cut offs for
T2* have not yet been clearly established, the abovemen-
tioned classification is widely used in clinical practice. For
the liver, we used the conversion from T2* to LIC, by
using the formula, 0.202+0.0254xR2* adapted from
Wood et al. [17] and is also the calculation used by our
MR service. The heavily iron loaded group includedJournal of Cardiovascular Magnetic Resonance 2009, 11:20 http://www.jcmr-online.com/content/11/1/20
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patients with T2* < 1.6 ms (16.1 mg/g dw), moderate ³
1.6 and < 4.0 (6.6–16.1 mg/g dw) and mild ³ 4 and < 9
ms (3–6.6 mg/g dw). Acceptable levels were those ³ 9 ms
(<3 mg/g dw) [17,18].
We also determined whether any patients who were above
the acceptable levels (Cardiac T2* ³ 20 ms and hepatic
T2* ³ 9.0 ms) fell below those levels.
Clinical practice differs from designed trials in that many
parameters cannot be controlled. All assessments were
therefore made according to the Intention to Treat i.e.
compliance with chelation therapy was not assessed or
taken into account for the purposes of this study, time
intervals between MR scans were not consistent and man-
agement changes were often related to the degree of per-
ceived iron load. In addition, dose responses were not
analysed.
The Ethics Committee of the hospital approved permis-
sion for medical review, waiver of informed consent and
anonymous publication of data according to the Declara-
tion of Helsinki.
Statistical analysis
Data on each patient were retrospectively recorded from
the patient histories. The effect of the chelation regime in
reducing iron was then analysed longitudinally. Continu-
ous variables are presented as mean ± SD while categorical
variables are described using absolute and relative fre-
quencies. Means were compared by Student's t-test. Wher-
ever sample sizes were less than 30 or in cases of extremely
skewed distributions, Wilcoxon's matched-pairs signed-
ranks or the Mann-Whitney test were used. Hypotheses on
whether the mean of a continuous variable differed signif-
icantly between more than two groups were assessed by
analysis of variance (ANOVA). Alternatively, the Kruskal
Wallis test was used when the sample sizes were small.
Multiple hypothesis testing was corrected by the Bonfer-
roni method. Categorical variables were tested using
Fisher's exact test. Wherever descriptive data appear for
each treatment group, it refers to the patients who had at
least two MR scans when exposed to a particular regime.
In this way a patient may contribute information to more
than one group. For example, a patient, who has had two
MR scans and has been on DFO during that period and
then switched to Comb with a subsequent MR, will be
included in the DFO group once and in the Comb group
once. This patient will then contribute information
regarding MR changes and descriptive statistics such as age
to both groups.
The statistical method described below depends on the
normality of the data to be analyzed. For this reason, we
chose to analyse T2* values because these appear to have
the least deviation from the Normal distribution com-
pared to R2* (1000/T2*), CIC, LIC or other log transfor-
mations of T2* values and have a rather more symmetric
distribution than any of those (analyses available from
authors). After extraction of the results, we transformed
the change in T2* to mg/gdw, using the above mentioned
equation from data from Wood et al [16] in order to elim-
inate the lack of linearity between tissue iron and T2*,
accepting that at this time, no definite calibration curve
between T2* and cardiac iron for humans has been estab-
lished. The described approach fulfils the necessary statis-
tical assumptions and translates the results to tissue iron
concentration which is more relevant and interpretable to
clinicians than a number value (in ms or sec-1).
In order to evaluate the rate of change of T2* (r-T2*), a
repeated measurements regression analysis with corre-
lated errors was applied. Our data set consisted of 6 obser-
vations per person (maximum number of MR scans in our
population). For those who had less than 6 MR scans the
remaining values were considered missing. Our data were
imbalanced because of the varying time intervals between
MR scans. For example the second MR for one individual
might have been at 12 months and for another it may
have been at 20 months. In the same way the third MR
could have been at no fixed time after the second. For this
reason we incorporated time in a continuous manner
(and not as pre-fixed categorical time point) using four
different time covariates that measured time of exposure
for each treatment group, allowing for a direct estimation
of the effect of each regime on the rate of change of T2* (r-
T2*). Whenever a patient switched to a different regime
the respective time covariate between MR scans under the
specific medication began to be measured. Assuming that
the rate of change of T2* (r-T2*) depends on the level of
siderosis we used a time-varying categorical covariate
(four levels of siderosis for heart and liver as described ear-
lier) to adjust for the previous (baseline) measurement of
T2*. Furthermore, in order to quantify the rates of change
of T2* for each regime within each level of siderosis we
used four interaction terms between the 4 time variables
and the time-varying baseline. Finally the potential effect
of gender and age was also assessed with the latter being
incorporated in the model in a time-varying manner. Due
to the relatively large sample size an unstructured covari-
ance matrix describing the correlation of the repeated
measurements within the same person was used. The sig-
nificance of the effect of each term was evaluated by the
Wald test.
In the "Initial interval analysis", we only analyzed the first
two MR scans with a minimal interval of 12 months on
each regime. Initially we assessed the response (change in
cardiac iron – D CIC and the change in hepatic iron – D
LIC) to each regime. A comparison of D CIC or D LIC
between the four regimes without taking time into
account would be inappropriate. In order to evaluate theJournal of Cardiovascular Magnetic Resonance 2009, 11:20 http://www.jcmr-online.com/content/11/1/20
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differences of the rates of change of CIC and LIC between
the four treatment regimes, subsequently, annual rates
were calculated (annual rate: r-CIC = D CIC/time and r-
LIC = D LIC/time with the time interval measured in
years). All statistical procedures were performed using SAS
V8 statistical software (SAS Institute Inc., Cary, NC, USA)
and Stata 8.0 (StataCorp, College Station, Texas.USA).
Results
General
Two hundred and thirty two patients had more than one
MR with a total of 652 studies. 83% of patients had 2 or 3
studies while 17% had 4 to 6.
Mean baseline ages (years) did not differ significantly
between treatment groups (DFO 29.4, DFP 29.8, Comb
28.9 and DFX 27.5 years, ANOVA F test p = 0.17) the male
female proportions differed significantly in that more
women were on DFX than men. Table 1 shows the mean
baseline cardiac and hepatic T2* values for each group
and the time of exposure to each chelation regime
between MR scans.
In both types of analysis, patients whose baseline levels
were acceptable (Cardiac T2* ³ 20 ms, Hepatic T2* ³ 9
ms) were analyzed but are not shown, as their results were
not of clinical significance.
Cardiac results
The hypothesis that the rate of change of T2* depends on
baseline iron level was confirmed by the repeated meas-
urements analysis. The interaction term between the rate
of change in T2* and the baseline level of siderosis
appears significant in the case of DFO, DFP and Comb,
but not in the case of DFX. Based on these results all the
comparisons are reported before and after stratification.
The estimated annual rates of change in T2*(r-T2*) for
each regime according to the severity of the cardiac iron
loading (results adjusted for age – gender was not signifi-
cant), are presented in figure 1. Only DFP or Comb dem-
onstrated significant improvement in cardiac T2* at all
levels of cardiac iron loading.
Due to the non-linear relationship between T2* and CIC,
the estimated constant rate of change of T2* within each
severity group corresponds to a variable rate of change for
CIC within the same severity group. For this reason, we
produced estimates of the annual change of CIC for base-
line measurements of 5, 11 and 17 ms (Figure 2, top
panel). These values represent, more or less, the middle of
each severity range. A quadratic fit curve based on many
estimations of r-CIC according to a wide range of values
of the baseline T2* (2–18 ms) is also presented in Figure
2 for each treatment regime (bottom panel). The observed
increasing trend for r-CIC for baseline T2* values > 15 ms
is due to the discontinuous form of iron severity grouping
which produced overlapping of the estimated r-CIC
between the three iron load groups. This would have been
less likely to occur if an extremely large number of
patients was available, allowing for a very narrow catego-
rization.
In the "Initial interval analysis", Wilcoxon signed-rank
test showed a significant reduction of CIC (DCIC, mg/
gdw) in the DFP and the Comb groups, but not in the
DFO and the DFX groups. Due to the variability in the rate
of change in T2* seen in the repeated measurement anal-
ysis, we performed the analysis after stratifying for the
baseline iron load level (Table 2). In this analysis, Comb
was effective at all levels of iron load, DFP at moderate
and mild levels and DFO in the heavy loaded patients.
Due to the significant difference in the time periods of
exposure to the chelation regime, the annual rate of
change of T2* in the "Initial interval analysis" were ana-
lysed and compared. These results are presented in figure
3.
Of the patients who had T2* ³ 20 ms only one demon-
strated a fall in cardiac T2* to less than 20 ms over the first
interval. This patient was on Comb.
Hepatic results
The "Initial interval analysis" (Wilcoxon signed-rank test)
showed a significant reduction of LIC in the Comb and
the DFX groups, but not in the DFP or the DFO groups
(Table 3). The D LIC was not constant across the three lev-
els of liver iron load for each regime. The results of the
stratified analysis are shown in table 3. Combination ther-
apy caused a significant reduction in LIC at all levels of
Table 1: Baseline T2* values and period of exposure to each chelation regime between MR scans.
Parameter, mean (SD) Treatment
DFO DFP DFP & DFO DFX ANOVA F-test p-value
Heart T2* 21.4 (12.6) 15.7 (9.6) 16.6 (10.8) 27 (9.5) <0.0001
Liver T2* 6.2 (5.5) 10.6 (9.3) 5 (5.3) 5.3 (6.8) 0.0004
Exposure period (months) 24 (11.5) 25.6 (13.2) 26.8 (12.6) 17.3 (7) <0.0001
Intervals between MR scans (months) 19.1 (9.6) 17.2 (11.3) 19 (9.5) 14 (4.5) 0.0001Journal of Cardiovascular Magnetic Resonance 2009, 11:20 http://www.jcmr-online.com/content/11/1/20
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haemosiderosis while DFX reduced the LIC in severely
and moderately loaded patients.
We analyzed the estimated mean difference of annual rate
of change of LIC (r-LIC) for all four regimes using the
same approach as for the heart. Non-stratified analysis
showed significant differences in r-LIC among the four
treatments (DFO: r-LIC = 0.50 (increase) mg/g dw, n = 36;
DFP: r-LIC = -3.69 mg/g dw, n = 14; Comb: r-LIC = -3.14
mg/g dw, n = 99; DFX: r-LIC = -2.15 mg/g dw, n = 53;
Kruskal Wallis test: p < 0.001). Significant comparisons
(Mann-Whitney test) were between Comb and DFO (p <
0.001), and between DFX and DFO (p = 0.02) while
between DFP and DFO the result was marginally non-sig-
nificant (p = 0.066). The analysis of r-LIC was repeated
after stratification revealing the following significant
results:
￿ In the moderate group, the annual rate of change in
LIC was 0.51 (increase) mg/g dw with DFO (n = 11), -
1.27 DFP (n = 6), – 2.52 Comb (n = 45), and -1.30
with DFX (n = 16). These differences were significant
between the DFO and Comb groups (p = 0.01).
￿ In the mild group with DFO the annual rate of
change in LIC was 0.36 mg/g dw (n = 20), DFP 0.42 (n
= 5), Comb -1.00 (n = 29), and DFX -0.19 (n = 16)
(underlined result indicate increase in LIC). These dif-
ferences were significant only between the DFO and
Comb groups (p = 0.004).
There were no significant differences in the severe group.
Table 4 shows the number of patients who at some time
had an acceptable level of hepatic T2* (³ 9 ms) and whose
T2* fell below that level. Comb had significantly fewer
falls below the acceptable level than the other three
regimes. The risk of the hepatic T2* falling below 9 ms (>3
mg/g dw) was higher in patients taking DFO, DFX and
DFP compared to those on Comb (logistic regression
analysis): DFO vs Comb: OR = 8 (p = 0.029); DFX vs
Comb: OR = 24 (p = 0.001); DFP vs Comb OR = 16 (p =
0.002). All other comparisons were not significant. Table
5 shows the fall in LIC (mg/g dw) in those patients accord-
ing to the regime they were receiving. The increase in LIC
was greatest as follows: DFX>DFP>DFO>Comb (Kruskal
Wallis test – result marginally non-significant p = 0.059).
Discussion
The knowledge of the degree of organ specific iron load-
ing and the ability to tailor iron chelation regimes are sig-
nificant factors in the improved survival recently reported
Rate of change of T2* according to severity of baseline cardiac iron load and chelation regime prescribed Figure 1
Rate of change of T2* according to severity of baseline cardiac iron load and chelation regime prescribed.
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[4]. The aim of this study was to evaluate effects of iron
chelators in a clinical setting rather than in controlled
clinical trials. The outcomes confirm both findings from
other studies and observations that have been seen in clin-
ical practice.
One of the advantages of this study is that it is from a sin-
gle large thalassaemia unit, which practices relatively con-
sistent management. To date, there have been no reports
on longitudinal measurements of iron load assessment
with T2* that have analysed the efficacy of all four cur-
rently available chelation regimes. The only available
report that analyzed repeated measurements assessed
other parameters, not the rates of change or the efficacy of
the available chelators [19]. The large number of patients
followed with repeated studies allows the representation
of time trends that might be expected according to the
chelation regime prescribed. The type of analysis used
demonstrated that the rate of change in T2* in the heart
and liver varies according to the degree of baseline iron
loading.
With respect to the heart, the lack of significant reduction
in iron by standard treatment with DFO (30–40 mg/kg/
Estimated annual rates of change of CIC and R2* Figure 2
Estimated annual rates of change of CIC and R2*. Estimated annual rates of change of CIC (r-CIC, mg/gdw per year) 
and R2* (sec-1) for each regime at starting T2* levels of 5, 11 and 17 ms (top panel) and quadratic fit curves respectively (bot-
tom panel) as evaluated from the "repeated measurements analysis".
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Table 2: Mean estimated† change in CIC mg/gdw (D CIC) according to severity of cardiac siderosis between first two MR scans ("Initial 
interval analysis" -minimum interval 12 months).
Overall Stratified
Heavy Moderate Mild
Regime Time* (years) n D CIC p n D CIC p n D CIC p n D CIC p
DFO 1.83 32 -0.23 0.43 9 -1.3 0.028 16 0.16 0.71 7 +0.27 0.95
DFP 1.80 26 -0.64 0.001 7 -0.57 0.49 13 -0.82 0.002 6 -0.36 0.027
Comb 1.80 88 -0.78 <0.001 36 -1.12 0.002 30 -0.69 <0.001 22 -0.41 <0.001
DFX 1.33 16 +0.66 0.10 6 +1.43 0.24 4 +0.73 0.46 6 -0.15 0.17
*Time = mean time (in years) between MR scans.
†Wilcoxon matched-pairs signed rank test
Annual rate of change of Estimated Cardiac Iron Concentration r-CIC comparing significance between the treatment regimes  (Initial interval analysis) Figure 3
Annual rate of change of Estimated Cardiac Iron Concentration r-CIC comparing significance between the 
treatment regimes (Initial interval analysis). Significant comparisons (Mann Witney Test) ￿ Overall: DFP -v- DFX p < 
0.001, Comb -v- DFX p < 0.001 ￿ Severe: Comb -v- DFX p = 0.04, DFX -v- DFO p = 0.07 (marginally non-significant) ￿ Moder-
ate: DFP -v- DFO p = 0.06, DFP -v- DFX p = 0.036, Comb -v- DFO p = 0.07, Comb -v- DFX p = 0.07 (both marginally non-sig-
nificant) ￿ Mild: No comparison was statistically significant.
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infusion 5–6 days per week) in the mild and moderate
iron loaded patients could be attributed to the relatively
small sample sizes in the stratified analysis ("Initial inter-
val analysis") or poor compliance. In the heavily loaded
group the improvement was significant. This discrepancy
may be related to better compliance in those patients who
were concerned about their cardiac iron and to higher
dosage and frequency of use of DFO. This result is consist-
ent with those in patients with heavy cardiac iron load
and cardiac dysfunction who were treated with intensive
regimes with DFO continuously intravenously [20]. How-
ever in the overall analysis the results are derived from 32
patients and the lack of efficacy is in accordance with the
incidence of cardiac related deaths and the onset of de
novo cardiac disease in patients on DFO [21,22]. These
observations are also consistent with studies that showed
that despite DFO treatment, between 56 and 65% of
patients had cardiac iron loading and 11–25% had exces-
sive loading [8-10]. The results with DFP showing a signif-
icant rate of improvement in cardiac iron conform with
the Greek and Italian randomised controlled study which
showed superiority of DFP over DFO in its ability to
improve T2* [18]. They also support findings of the lower
incidence of cardiac deaths and de novo cardiac events
from the two abovementioned Italian Studies [21,22].
Both a randomised placebo controlled study and a non-
randomised study from Sardinia showed that the most
rapid clearance of cardiac iron could be effected by Comb,
consistent with this study [23,24]. They are also consistent
with at least three case reports that demonstrated the
reversal of cardiac failure with the use of combination
therapy [25-27]. For a similar reversal with DFO, intensi-
fication of the therapy is necessary, usually by continuous
intravenous infusions [20,28,29]. No patients in our
study were on such intensive therapy. If such therapy is
considered necessary, Comb is chosen by most patients,
provided they do not have any contraindication to that
therapy.
As we did not assess compliance, this study demonstrates
relatively realistic outcomes that can be expected in a clin-
ical setting. It is likely that poorly compliant patients may
have negatively influenced outcomes but this confirms
the value of this type of study compared to a strict clinical
trial. The one patient who showed an increase in cardiac
iron load most likely did not accept the therapy pre-
scribed. The same patient demonstrated a further deterio-
ration on her subsequent MR, as both liver and heart iron
increased, consistent with poor compliance.
Table 3: Mean estimated† change in LIC mg/gdw (D LIC) according to severity of hepatic siderosis between first two MR scans 
(minimum interval 12 months).
Overall Stratified
Heavy Moderate Mild
Regime Time* (years) n D LIC p n D LIC p n D LIC p n D LIC p
DFO 2.0 36 +1.34 0.095 5 +2.31 0.68 11 +1.64 0.21 20 +0.94 0.27
DFP 1.9 14 -6.2 0.068 3 n.a.¶ n.a. 6 -0.97 0.3 5 +2.68 0.5
Comb 1.8 99 -4.19 <0.001 25 -9.18 0.003 45 -3.27 <0.001 29 -1.33 0.004
DFX 1.3 53 -2.80 0.005 21 -5.38 0.042 16 -2.08 0.042 16 -0.14 0.35
*Time = mean time (in years) between MR scans.
†Wilcoxon matched-pairs signed rank test
¶ Numbers too small for analysis
Table 4: Number of patients whose hepatic T2* fell below 9 ms (>3 mg/gdw) according to chelation regime
Medication
DFP Comb DFX DFO Total
Fall < 9, n (%)
Unchanged, n (%) 7 (50) 32 (94) 4 (40) 8 (66.7) 51 (73)
Total, n (%) 14 (100) 34 (100) 10 (100) 12 (100) 70 (100)
Fisher's exact: p < 0.001Journal of Cardiovascular Magnetic Resonance 2009, 11:20 http://www.jcmr-online.com/content/11/1/20
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As yet, there are no randomized prospective studies with
respect to the comparison of DFX with other regimes in
their effect on cardiac iron. One prospective study has
shown a significant reduction in cardiac iron with DFX
over a 12 months period, that also included a stratifica-
tion of patients using T2* <10 ms (7.4 – 8.2 ms geometric
mean difference with p = 0.0002) as cut off for severe iron
loading and between 10–20 ms for mild to moderate
(14.6–17.4 ms p < 0.0001). This study is from a subset of
patients who were participating in a clinical trial (EPIC)
and the mean dose of DFX was 32.6 mg/kg/day with only
4.4% receiving less than 30 mg/kg/day [30]. In addition,
two series of observations have demonstrated some bene-
fit with increased cardiac T2* [31,32]. Over a longer
period of observation, our results did not show a statisti-
cally significant difference in cardiac iron load in patients
on DFX which are similar to the findings of MR observa-
tions after 4 years for patients entered into preregistration
and extension phases of DFX studies [33] which showed
that among patients with baseline T2* values < 20 ms, 7
improved, of whom 2 patients normalised T2*, 3
remained stable (change £  0.2 ms) and 3 showed T2* dete-
rioration. Similarly, a large Italian multicentre observa-
tional study showed that patients on DFX had greater
cardiac iron load than those on DFO and DFP [34] after at
least 12 months on the respective therapies. The latter
report lacks baseline measurements of ferritin or T2* and
for this reason the lower T2* with DFX may be related to
higher initial total iron load. This may mean that patients
with greater iron load were prescribed DFX preferentially.
The difference between our observation and the Italian
observations [34] compared to the two abovementioned
prospective studies is most likely due to higher doses of
drug (30 mg/kg/day with the ability to escalate the dose to
over 40 mg/kg/day) used in those studies. The significance
of compliance and dose was also stressed in the clinical
follow up study [33]. In Europe DFX is not yet licensed
above 30 mg/kg/day. Further randomised studies to com-
pare DFX to other regimes in removing cardiac iron are
anticipated.
The results derived from the "Initial interval analysis" con-
firm to a certain extent the overall conclusions that the
repeated measurements produced. In some cases the
applied stratification reduced the ability to distinguish
statistically significant differences.
With respect to the liver, we did not use R2 for LIC deter-
mination [35] as our MR laboratory reports results to us
using the T2* method. As was the case in this study, the
lack of significant change in the LIC with DFO [36] and
DFP [18] has been demonstrated in the past, though in
general they have both been reported to reduce tissue iron
[37,38]. The result with DFP reflects the small number of
patients on that regime whose T2* was below the accept-
able levels of hepatic iron and for this reason power for
detecting statistical significance was reduced. The benefit
of Comb with respect to its significant reduction in
hepatic iron conforms to the abovementioned Sardinian
study [23]. With respect to DFX, the "Initial interval anal-
ysis" with the first two MR scans showed a significant
improvement in hepatic iron load at severe and moderate
loads, similar to the findings in a large clinical trial [38].
The increases observed in patients who initially had LIC
lower than 3 mg/gdw is difficult to explain. They may be
related to reduced compliance, in that patients may have
a false sense of security when they believe that their liver
iron is low or because the dose prescribed was reduced.
These outcomes should be taken into consideration if
changes in dosage of DFX are being considered.
Considering the risk of LIC increasing with DFX, DFP and
DFO in patients who initially had an acceptable LIC fre-
quent monitoring with MR in patients receiving mono-
therapy is recommended. This is essential in cases in
which they have been changed to monotherapy after they
had received Comb with effective clearance of iron.
Taking into account that negative iron balance with the
usual chelation regimes (dose and frequency) can only be
achieved in all patients with the use of Comb [39] its
superiority in maintaining patients at acceptable levels is
understandable.
The drawbacks of our study were that it was not prospec-
tive, the prescription of a particular regime was made on
clinical grounds and not on randomisation, the time
period between MR scans was variable, we did not take
into account whether the patients were splenectomised
nor assess the annual red cell consumption and rate of
iron loading. The latter has been shown to be important
with respect to choice of dose of chelators [39,40]. In
addition, patients on DFO, DFP and Comb were on those
regimes for significantly longer than patients who
received DFX. The resulting potential selection bias was
diminished by stratified analysis which allowed compari-
son of patients with similar baseline characteristics. The
Table 5: Mean increase in hepatic iron in mg/gm/dry weight in 
patients who had an acceptable level of hepatic iron and who 
then fell below that level, depending on their chelation regime.
Treatment Increase in hepatic iron
n Mean Range
DFO 4 3.5 0.6–10.8
DFP 7 4.6 1.9–13.2
Comb 2 0.8 0.6–1.0
DFX 6 7.3 1.2–15.5
Kruskal-Wallis test if means differ among groups: p = 0.059Journal of Cardiovascular Magnetic Resonance 2009, 11:20 http://www.jcmr-online.com/content/11/1/20
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problem with the variable time intervals was taken into
account by incorporating time into the repeated measure-
ments analysis and assessing rates of change with the "Ini-
tial interval analysis", including the restriction that a
minimum of twelve months between the studies was nec-
essary. The latter approach in the "Initial interval analysis"
allowed sufficient time for each regime to demonstrate its
capabilities and the usage of rates of change allowed for
comparison of the data. In addition, we did not assess
compliance nor make the analyses according to the doses
of medications. In several instances the patients only had
T2* of the heart measured thus explaining the smaller
number of observations on the liver. This only rendered
the performance of the repeated measurement analysis for
the liver inappropriate, but did not have any effect on the
"Initial interval analysis". In some cases the small number
of patients in some sub-groups may have reduced the
power to detect significant changes. The use of CIC was
derived from a formula that was based on experimental
data and not on calibration with human cardiac tissue.
However the CIC results are compatible with the autopsy
findings in four patients who died of cardiac iron loading
during the 1970's [41]. More specifically the CIC in the
hearts of those patients after being divided into smaller
slices for analysis was heterogeneously between 0.49 and
2.0% dry weight (equivalent to 4.9 and 20 mg/gdw which
according to the formula we used is equivalent to T2* 4.7
and 1.3 ms respectively).
The mean baseline cardiac T2* was greatest in patients on
DFX. This reflects current practice in our unit in that we
tended to recommend this regime to patients whom we
knew did not have excessive cardiac iron. Conversely,
patients who were taking DFP had the highest hepatic T2*
levels (low LIC), which is consistent with our clinical prac-
tice in that DFP is not our first choice when aiming to
achieve a significant reduction in hepatic iron. It can be
seen that the largest group of patients were those taking
Comb. The explanation for this is that prior to 1999, prac-
tically all of our patients were exposed only to DFO and
many patients had excessive cardiac iron. As it was becom-
ing recognised that the most effective regime for reducing
cardiac iron was use of Comb [42], this regime was recom-
mended to many patients.
Conclusion
The management of transfusion dependent thalassaemia
has been revolutionised over the last 10 – 15 years. This is
a result of both the availability of better and non-invasive
methods of accurately assessing iron load in the heart and
liver and the option of tailoring chelation according to the
degrees of iron load using any of the three chelators or
combinations thereof. Comb therapy is best in reducing
both cardiac and hepatic iron, while DFP and DFX mono-
therapies are effective in the heart and liver respectively. If
reduction of iron load is regarded as being relatively
urgent, combining DFP and DFO is the most appropriate
option, provided the patients have no contraindication to
such therapy. All these results represent findings that can
be expected in the real life clinical setting compared to
clinical trials. Desirable options for future research
include testing the efficacy of combinations of DFO/DFX
and DFP/DFX. The treatment of no other formerly fatal
genetic disease has progressed as far as that of thalassae-
mia. With current advances, survival and well-being
should continue to improve even more.
Competing interests
VB is a remunerated consultant with ApoPharma Inc and
a consultant with Novartis Inc with respect to the develop-
ment of desferasirox, has received honoraria from Demo
AE (Greece) and served on the Advisory Board of ApoP-
harma and has attended Novartis sponsored meetings on
iron chelation.
GC, PG, KZ have no interests to declare.
EB and VL have been remunerated for clinical trials from
both ApoPharma Inc and Novartis Inc and have attended
sponsored meetings from both. VL has also served on an
ApoPharma advisory board.
Authors' contributions
All authors were involved in determining the design of the
trial and all except for VL were involved in the data entry.
GC performed the statistical analysis. The paper was writ-
ten by VB, GC and VL with contributions from the other
authors.
Acknowledgements
We thank both Professors C. Kattamis and R. Grady for their review of the 
article and constructive criticism.
References
1. Ladis V, Chouliaras G, Berdousi H, Kanavakis E, Kattamis C: Longi-
tudinal study of survival and causes of death in patients with
thalassemia major in Greece.  Ann N Y Acad Sci 2005,
1054:445-450.
2. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD,
Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, et
al.: Survival and complications in patients with thalassemia
major treated with transfusion and deferoxamine.  Haemato-
logica 2004, 89:1187-1193.
3. Modell B, Khan M, Darlison M: Survival in beta-thalassaemia
major in the UK: data from the UK Thalassaemia Register.
Lancet 2000, 355:2051-2052.
4. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ:
Improved survival of thalassaemia major in the UK and rela-
tion to T2* cardiovascular magnetic resonance.  J Cardiovasc
Magn Reson 2008, 10:42.
5. Caro JJ, Ward A, Green TC, Huybrechts K, Arana A, Wait S, Elefth-
eriou A: Impact of thalassemia major on patients and their
families.  Acta Haematol 2002, 107:150-157.
6. Aessopos A, Farmakis D, Hatziliami A, Fragodimitri C, Karabatsos F,
Joussef J, Mitilineou E, Diamanti-Kandaraki E, Meletis J, Karagiorga M:
Cardiac status in well-treated patients with thalassemia
major.  Eur J Haematol 2004, 73:359-366.
7. Berdoukas V, Dakin C, Freeman A, Fraser I, Aessopos A, Bohane T:
Lack of correlation between iron overload cardiac dysfunc-Journal of Cardiovascular Magnetic Resonance 2009, 11:20 http://www.jcmr-online.com/content/11/1/20
Page 11 of 11
(page number not for citation purposes)
tion and needle liver biopsy iron concentration.  Haematologica
2005, 90:685-686.
8. Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, Nair
SV, Anderson LJ, Walker JM, Pennell DJ: Myocardial iron loading
in patients with thalassemia major on deferoxamine chela-
tion.  J Cardiovasc Magn Reson 2006, 8:543-547.
9. Aessopos A, Fragodimitri C, Karabatsos F, Hatziliami A, Yousef J, Gia-
koumis A, Dokou A, Gotsis ED, Berdoukas V, Karagiorga M: Cardiac
magnetic resonance imaging R2* assessments and analysis of
historical parameters in patients with transfusion-depend-
ent thalassemia.  Haematologica 2007, 92:131-132.
10. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD: Myocardial
iron loading in transfusion-dependent thalassemia and sickle
cell disease.  Blood 2004, 103:1934-1936.
11. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D,
Giardini C, Galimberti M, Polchi P, Lucarelli G: Hepatic iron con-
centration and total body iron stores in thalassemia major.
N Engl J Med 2000, 343:327-331.
12. Borgna-Pignatti C, Vergine G, Lombardo T, Cappellini MD, Cianciulli
P, Maggio A, Renda D, Lai ME, Mandas A, Forni G, et al.: Hepatocel-
lular carcinoma in the thalassaemia syndromes.  Br J Haematol
2004, 124:114-117.
13. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH,
Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ: Cardiovas-
cular T2-star (T2*) magnetic resonance for the early diagno-
sis of myocardial iron overload.  Eur Heart J 2001, 22:2171-2179.
14. Kattamis A, Ladis V, Berdousi H, Kelekis NL, Alexopoulou E, Papa-
sotiriou I, Drakaki K, Kaloumenou I, Galani A, Kattamis C: Iron che-
lation treatment with combined therapy with deferiprone
and deferioxamine: a 12-month trial.  Blood Cells Mol Dis 2006,
36:21-25.
15. Westwood MA, Firmin DN, Gildo M, Renzo G, Stathis G, Markissia
K, Vasili B, Pennell DJ: Intercentre reproducibility of magnetic
resonance T2* measurements of myocardial iron in thalas-
saemia.  Int J Cardiovasc Imaging 2005, 21:531-538.
16. Wood JC, Otto-Duessel M, Aguilar M, Nick H, Nelson MD, Coates
TD, Pollack H, Moats R: Cardiac iron determines cardiac T2*,
T2, and T1 in the gerbil model of iron cardiomyopathy.  Cir-
culation 2005, 112:535-543.
17. Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD,
Coates TD: MRI R2 and R2* mapping accurately estimates
hepatic iron concentration in transfusion-dependent tha-
lassemia and sickle cell disease patients.  Blood 2005,
106:1460-1465.
18. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A,
Gotsis ED, Tanner MA, Smith GC, Westwood MA, et al.: Rand-
omized controlled trial of deferiprone or deferoxamine in
beta-thalassemia major patients with asymptomatic myo-
cardial siderosis.  Blood 2006, 107:3738-3744.
19. Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC: Longitudi-
nal analysis of heart and liver iron in thalassemia major.  Blood
2008, 112:2973-2978.
20. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke
B, Porter JB, Walker JM, Pennell DJ: Myocardial iron clearance
during reversal of siderotic cardiomyopathy with intrave-
nous desferrioxamine: a prospective study using T2* cardio-
vascular magnetic resonance.  Br J Haematol 2004, 127:348-355.
21. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC,
Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H,
Cnaan A: Cardiac morbidity and mortality in deferoxamine-
or deferiprone-treated patients with thalassemia major.
Blood 2006, 107:3733-3737.
22. Piga A, Gaglioti C, Fogliacco E, Tricta F: Comparative effects of
deferiprone and deferoxamine on survival and cardiac dis-
ease in patients with thalassemia major: a retrospective
analysis.  Haematologica 2003, 88:489-496.
23. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A,
Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ: A rand-
omized, placebo-controlled, double-blind trial of the effect
of combined therapy with deferoxamine and deferiprone on
myocardial iron in thalassemia major using cardiovascular
magnetic resonance.  Circulation 2007, 115:1876-1884.
24. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A,
Pibiri M, Nair SV, Walker JM, Pennell DJ: Combined chelation
therapy in thalassemia major for the treatment of severe
myocardial siderosis with left ventricular dysfunction.  J Cardi-
ovasc Magn Reson 2008, 10:12.
25. Wu KH, Chang JS, Tsai CH, Peng CT: Combined therapy with
deferiprone and desferrioxamine successfully regresses
severe heart failure in patients with beta-thalassemia major.
Ann Hematol 2004, 83:471-473.
26. Tsironi M, Deftereos S, Andriopoulos P, Farmakis D, Meletis J, Aes-
sopos A: Reversal of heart failure in thalassemia major by
combined chelation therapy: a case report.  Eur J Haematol
2005, 74:84-85.
27. Tavecchia L, Masera N, Russo P, Ciro A, Vincenzi A, Vimercati C,
Masera G: Successful recovery of acute hemosiderotic heart
failure in beta-thalassemia major treated with a combined
regimen of desferrioxamine and deferiprone.  Haematologica
2006, 91:ECR19.
28. Davis BA, Porter JB: Long-term outcome of continuous 24-
hour deferoxamine infusion via indwelling intravenous cath-
eters in high-risk beta-thalassemia.  Blood 2000, 95:1229-1236.
29. Miskin H, Yaniv I, Berant M, Hershko C, Tamary H: Reversal of car-
diac complications in thalassemia major by long-term inter-
mittent daily intensive iron chelation.  Eur J Haematol 2003,
70:398-403.
30. Pennell DJ, Porter JB, Cappellini MD, Li C-K, Aydinok Y, Chan LL,
Kattamis A, Smith G, Habr D, Domokos G, Hmissi A, Taher A: Effi-
cacy and safety of deferasirox (Exjade) in reducing cardiac
iron in patients with b-thalassemia major: Results from the
cardiac substudy of the EPIC trial.  ASH Annual Meeting, San Fran-
cisco, USA, 6–9 December  2008.
31. Eleftheriou P, Tanner M, Pennell D, Porter J: Response of myocar-
dial T2* to oral deferasirox monotherapy for 1 year in 29
patients with transfusion-dependent anaemias; A subgroup
analysis.  Haematologica 2006, 91(Suppl 1):abst 999.
32. Wood J, Thompson A, Paley C, Kang B, Giardina P, Harmatz P, Virkus
J, Coates T: Deferasirox (Exjade) monotherapy significantly
reduces cardiac iron burden in chronically transfused b-tha-
lassemia patients: An MRI T2* study.  ASH Annual Meeting, San
Francisco, USA, 6–9 December  2008.
33. Garbowski M, Eleftheriou P, Pennell D, Tanner M, Porter JB: Impact
of Compliance, Ferritin and LIC on Long-Term Trends in
Myocardial T2* with Deferasirox.  In ASH Annual Meeting Volume
112. San Francisco: Blood; 2008:49-50. 
34. Pepe A, Favilli B, Positano V, Cianciulli P, Spasiano A, Capra M,
Borgna-Pigniatti C, Putti MC, Casini T, Romeo MA, Bisconte MG,
Filosa A, Caruso V, Quarta A, Pitrolo L, De Sanctis V, Gerardi C, Mag-
gio C, Pietrangelo A, Lombardi M: Comparison of deferasirox,
deferiprone and desferrioxamine effectiveness on myocar-
dial iron concenrations and biventricular function by quanti-
tative MRI in thalassemia major.  ASH Annual Meeting, San
Francisco, USA, 6–9 December  2008.
35. St Pierre TG, Clark PR, Chua-Anusorn W: Measurement and
mapping of liver iron concentrations using magnetic reso-
nance imaging.  Ann N Y Acad Sci 2005, 1054:379-385.
36. Berdoukas V, Bohane T, Tobias V, De Silva K, Fraser I, Aessopos A,
Lindeman R: Liver iron concentration and fibrosis in a cohort
of transfusion-dependent patients on long-term desferriox-
amine therapy.  Hematol J 2005, 5:572-578.
37. Wu SF, Peng CT, Wu KH, Tsai CH: Liver fibrosis and iron levels
during long-term deferiprone treatment of thalassemia
major patients.  Hemoglobin 2006, 30:215-218.
38. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L,
Aydinok Y, Kattamis A, Kilinc Y, Porter J, et al.: A phase 3 study of
deferasirox (ICL670), a once-daily oral iron chelator, in
patients with beta-thalassemia.  Blood 2006, 107:3455-3462.
39. Grady R, Berdoukas V, Rachmielewitz EA, Giardina PJ: Optimising
chelation therapy: Combining deferiprone and deferoxam-
ine.  Blood 2000, 96:604.
40. Cohen AR, Glimm E, Porter JB: Effect of transfusional iron intake
on response to chelation therapy in beta-thalassemia major.
Blood 2008, 111:583-587.
41. Modell B, Berdoukas V: The Clinical Approach to Thalassaemia 1st edi-
tion. New York: Grune & Stratton; 1984. 
42. Wonke B, Wright C, Hoffbrand AV: Combined therapy with
deferiprone and desferrioxamine.  Br J Haematol 1998,
103:361-364.